Evaluation of Omeprazole, Lansoprazole, Pantoprazole, and Rabeprazole in the Treatment of Acid-Related Diseases
Authors:
- Lynda S. WelageLWLynda S. Welage
- Rosemary R. BerardiRBRosemary R. Berardi
- 1 January 2000
- journal article
- review article
- Published by Elsevier in Journal of the American Pharmaceutical Association
- Vol. 40 (1) , 52-62
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Guidelines for the management of Helicobacter pylori infectionAmerican Journal of Gastroenterology, 1998
- Proton-pump inhibitors in acid-related diseasesAmerican Journal of Health-System Pharmacy, 1998
- Helicobacter pylori: rational management optionsThe American Journal of Medicine, 1998
- OmeprazoleDrugs, 1998
- Proton Pump InhibitorsDrugs, 1998
- Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype*Clinical Pharmacology & Therapeutics, 1997
- LansoprazoleDrugs, 1997
- The role of antisecretory drugs in the treatment of Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 1997
- PantoprazoleDrugs, 1996
- Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation*Clinical Pharmacology & Therapeutics, 1995